Mark R Gilbert: Influence Statistics

Mark R Gilbert

Mark R Gilbert

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA | Center for Cancer Research and Neuro-Oncology Branch (MRG, TSA), ...

Mark R Gilbert: Expert Impact

Concepts for which Mark R Gilbert has direct influence: Recurrent glioblastoma , Newly diagnosed glioblastoma , Bevacizumab patients , Radiation therapy , Recurrent ependymoma , Diagnosed glioblastoma , Adjuvant treatment .

Mark R Gilbert: KOL impact

Concepts related to the work of other authors for which for which Mark R Gilbert has influence: Brain metastases , Stereotactic radiosurgery , Intracranial ependymoma , Leptomeningeal metastasis , Radiation therapy , Gbm patients , Ependymal tumors .

KOL Resume for Mark R Gilbert

Year
2022

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA

2021

Department of Otolaryngology-Head and Neck Surgery, 204139University of Missouri Health Care, Missouri, MO, USA.

Neuro-Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

2020

National Institutes of Health, Bethesda, MD.

NIH/NCI/NOB

2016

Vijay Ramaswamy, Stephen C. Mack, Alvaro Lassaletta, Betty Luu, Florence M.G. Cavalli, Uri Tabori, Ute Bartels, Eric Bouffet, Cynthia E. Hawkins, James T. Rutka, Peter Dirks, and Michael D. Taylor, The Hospital for Sick Children; Vijay Ramaswamy, Kenneth Aldape, James T. Rutka, and Michael D. Taylor, University of Toronto; Kenneth Aldape, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario; Christopher Dunham and Juliette Hukin, British Columbia Children's Hospital; Juliette Hukin, University of British Columbia, Vancouver, British Columbia; David D. Eisenstat, Dorcas Fulton, and Frank K.H. van Landeghem, University of Alberta, Edmonton; Jennifer A. Chan, University of Calgary, Calgary, Alberta; Nada Jabado and Kevin Petrecca, McGill University, Montreal, Quebec, Canada; Thomas Hielscher, Kristian W. Pajtler, David T.W. Jones, Marcel Kool, Stefan M. Pfister, and Andrey Korshunov, German Cancer Research Center; Stefan M. Pfister, University Hospital Heidelberg, Heidelberg; Marc Remke, University Hospital Düsseldorf, Düsseldorf; Martin Mynarek, Stefan Rutkowski, and Katja von Hoff, University Medical Center Hamburg-Eppendorf, Hamburg; Ulrich Schüller, Ludwig-Maximilians-Universität, Munich, Germany; Stephen C. Mack, Cleveland Clinic Foundation, Cleveland; Maryam Fouladi, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Tong Lin, Amar Gajjar, Thomas E. Merchant, and David W. Ellison, St Jude Children's Research Hospital, Memphis; Lola B. Chambless, Vanderbilt Medical Center, Nashville, TN; Sridharan Gururangan, Roger E. McLendon, and Eric S. Lipp, Duke University, Durham; Jing Wu, University of North Carolina at Chapel Hill, Chapel Hill, NC; Mariarita Santi, Children's Hospital of Philadelphia; Lyndsey Emery, Hospital of the University of Pennsylvania, Philadelphia; Ronald L. Hamilton and Ian F. Pollack, University of Pittsburgh School of Medicine; Frank Lieberman, University of Pittsburgh Medical Cen

2015

From University of Alabama at Birmingham Comprehensive Cancer Center; City of Hope Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Yale Cancer Center/Smilow Cancer Hospital; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The University of Texas MD Anderson Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Roswell Park Cancer Institute; Duke Cancer Institute; UC San Diego Moores Cancer Center; University of Michigan Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; Massachusetts General Hospital Cancer Center; American Brain Tumor Association; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Stanford Cancer Institute; Fred & Pamela Buffet Cancer Center; Huntsman Cancer Institute at the University of Utah; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Moffitt Cancer Center; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; National Comprehensive Cancer Network.

2014

From University of Alabama at Birmingham Comprehensive Cancer Center; City of Hope Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The University of Texas MD Anderson Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Memorial Sloan Kettering Cancer Center; Roswell Park Cancer Institute; Duke Cancer Institute; UC San Diego Moores Cancer Center; American Brain Tumor Association; University of Michigan Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Massachusetts General Hospital Cancer Center; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Stanford Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; Huntsman Cancer Institute at the University of Utah; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Moffitt Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; and National Comprehensive Cancer Network.

2005

MD Anderson Cancer Center, University of Texas, Houston, Texas, USA

Prominent publications by Mark R Gilbert

KOL-Index: 10358 . PURPOSE: NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and ...
Known for Phase Iii | Grade Glioma | Risk Low | Nrg Oncology Rtog
KOL-Index: 8914 . PURPOSE: Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductive surgery and radiation therapy for posterior fossa ependymoma after accounting for molecular subgroup is not known. METHODS: Four independent nonoverlapping retrospective cohorts of posterior fossa ...
Known for Posterior Fossa | Cytoreductive Surgery | Epnpfa Epnpfb | Therapeutic Impact
KOL-Index: 3132 . Background: Medulloblastoma (MB) is a rare brain tumor occurring more frequently in children in whom research has been primarily focused. Treatment recommendations in adults are mainly based on retrospective data and pediatric experience; however, molecular features and treatment tolerance differ between the 2 age groups. In adults, prognostic tools are suboptimal, late recurrences are ...
Known for Adult Mb | Pediatric Experience | Molecular Features | Retrospective Data
KOL-Index: 2686 . The NCCN Guidelines for Central Nervous System Cancers provide multidisciplinary recommendations for the clinical management of patients with cancers of the central nervous system. These NCCN Guidelines Insights highlight recent updates regarding the management of metastatic brain tumors using radiation therapy. Use of stereotactic radiosurgery (SRS) is no longer limited to patients with 3 ...
Known for Central Nervous | Srs Patients | Stereotactic Radiosurgery | Radiation Therapy
KOL-Index: 2365 . Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemotherapy and radiation as the new standard for treating patients with pure or mixed anaplastic oligodendroglioma harboring the 1p/19q codeletion. For ...
Known for Central Nervous | Brain Metastases | Stereotactic Radiosurgery | Neoplasms Humans

Treatment of astrocytomas


[ PUBLICATION ]
KOL-Index: 1130 . PURPOSE OF REVIEW: Astrocytomas are the most common primary brain tumors. We will review recent developments in the understanding of the biology of these neoplasms and recent trials demonstrating promising improvements in the survival of patients with malignant gliomas. RECENT FINDINGS: Temozolomide along with radiation has become the standard of care for patients with newly diagnosed ...
Known for Malignant Gliomas | Brain Neoplasms | Tumors Review | Agents Alkylating
KOL-Index: 488 . PURPOSE: To investigate the toxicity profile and establish an optimal dosing schedule of zotiraciclib with temozolomide in patients with recurrent high-grade astrocytoma. PATIENTS AND METHODS: This two-stage phase I trial determined the MTD of zotiraciclib combined with either dose-dense (Arm1) or metronomic (Arm2) temozolomide using a Bayesian Optimal Interval design; then a randomized ...
Known for Bayesian Optimal

Key People For Recurrent Glioblastoma

Top KOLs in the world
#1
Roger Stupp
newly diagnosed glioblastoma radiation therapy adjuvant temozolomide
#2
Martin J van den Bent
recurrent glioblastoma response assessment brain metastases
#3
Michael Weller
glioma cells newly diagnosed glioblastoma multiple sclerosis
#4
Alba Ariela Brandes
recurrent glioblastoma elderly patients breast cancer
#5
Patrick Yung Chih Wen
recurrent glioblastoma brain metastases response assessment
#6
Warren P Mason
newly diagnosed glioblastoma adjuvant temozolomide phase iii

Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA | Center for Cancer Research and Neuro-Oncology Branch (MRG, TSA), National Cancer Institute, Bethesda, MD, USA. | Department of Otolaryngology-Head